Market Outlook:

Psoriatic arthritis (PsA) treatment typically begins with conventional DMARDs, such as methotrexate, and progresses to more-potent biologics or targeted oral therapies as needed. The U.S. market for conventional DMARD-refractory patients is increasingly crowded with multiple efficacious therapies, including six TNF-alpha inhibitors, the IL-17 inhibitor Cosentyx (Novartis), the IL-12/23 inhibitor Stelara (Janssen), and the first-approved oral targeted PsA therapy, Otezla (Celgene). In addition, the December 2017 FDA approvals of Xeljanz (Pfizer), an additional oral, first-in-class JAK inhibitor, and Taltz (Eli Lilly), a second-in-class IL-17 inhibitor, have expanded physicians’ treatment armamentarium for PsA and further increased the competition.

Questions Answered:

  • What patient shares do key therapies and brands garner by line of therapy in newly diagnosed PsA patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed PsA patients?
  • How have Xeljanz and Taltz been integrated into the treatment algorithm, and what are their sources of business?
  • What percentage of PsA patients receive drug therapy within three years of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within three years of diagnosis?
  • What percentage of PsA patients are treated with monotherapy versus combination therapy? What are the most commonly used combinations? What are the product-level compliance and persistency rates among drug-treated patients?
  • What are the product-level compliance and persistency rates among drug-treated patients?

Content Highlights:

  • Geographies: United States
  • Real World Data: Longitudinal patient-level claims data analysis
  • Key Drugs Covered:  Methotrexate, Humira, Enbrel, Remicade, Stelara, Cosentyx, Orencia, Otezla, Xeljanz, Taltz
  • Key Analysis provided:  Brand/therapy usage across longitudinal patient sample; newly diagnosed patient analysis; treatment initiation and progression; line of therapy analysis; combination therapy analysis; source of business for recently treated patients; persistency and compliance analysis; product-level patient flowcharts

Product Description:

Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.

Table of contents

  • Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis (US)
    • Treatment Algorithm: Claims Data Analysis-Psoriatic Arthritis-US PPT [May 2019]

Author(s): Ajay Puri, MBA

Ajay Puri is a Research Associate on the Immune and Inflammatory team at Decision Resources Group. He currently focuses on Inflammatory bowel disease (IBD). He holds a bachelor’s degree in Pharmacy and has earned his MBA in Pharmaceutical marketing from NIPER, Mohali. Prior to joining DRG, Ajay worked as a Business Research Associate (Oncology) at ZS Associates. He has worked on multiple client projects revolving around competitive intelligence, opportunity assessment, trend analysis, clinical trial analysis, and product/company profiling.  

Related Reports

Psoriatic Arthritis | Landscape & Forecast | Disease Landscape & Forecast

PsA, a disease characterized by flaky psoriatic skin lesions, erosive joint damage, and complicating comorbidities, remains poorly understood, underd...

View Details

Psoriatic Arthritis | Unmet Need | Detailed, Expanded Analysis (US & EU)

MARKET OUTLOOK Although TNF-alpha inhibitors remain the preferred choice for psoriatic arthritis (

View Details

Psoriatic Arthritis | Emerging Therapies | Xeljanz (tofacitinib) Psoriatic Arthritis - Wave 3 (US)

Xeljanz is the first-in-class JAK inhibitor approved for psoriatic arthritis (PsA) and the only other oral targeted ther...

View Details